Uniqure NV
NASDAQ:QURE

Watchlist Manager
Uniqure NV Logo
Uniqure NV
NASDAQ:QURE
Watchlist
Price: 17.29 USD 1.83% Market Closed
Market Cap: 842.7m USD
Have any thoughts about
Uniqure NV?
Write Note

Uniqure NV
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Uniqure NV
Total Current Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Uniqure NV
NASDAQ:QURE
Total Current Liabilities
$71.3m
CAGR 3-Years
19%
CAGR 5-Years
20%
CAGR 10-Years
18%
Pharming Group NV
AEX:PHARM
Total Current Liabilities
$79.8m
CAGR 3-Years
26%
CAGR 5-Years
-2%
CAGR 10-Years
20%
ProQR Therapeutics NV
NASDAQ:PRQR
Total Current Liabilities
€39.6m
CAGR 3-Years
5%
CAGR 5-Years
29%
CAGR 10-Years
N/A
argenx SE
XBRU:ARGX
Total Current Liabilities
$499.6m
CAGR 3-Years
27%
CAGR 5-Years
37%
CAGR 10-Years
69%
Merus NV
NASDAQ:MRUS
Total Current Liabilities
$80.1m
CAGR 3-Years
4%
CAGR 5-Years
20%
CAGR 10-Years
N/A
LAVA Therapeutics NV
NASDAQ:LVTX
Total Current Liabilities
$14.9m
CAGR 3-Years
27%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Uniqure NV
Glance View

Market Cap
842.7m USD
Industry
Biotechnology

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 463 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

QURE Intrinsic Value
15.99 USD
Overvaluation 8%
Intrinsic Value
Price

See Also

What is Uniqure NV's Total Current Liabilities?
Total Current Liabilities
71.3m USD

Based on the financial report for Sep 30, 2024, Uniqure NV's Total Current Liabilities amounts to 71.3m USD.

What is Uniqure NV's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
18%

Over the last year, the Total Current Liabilities growth was 4%. The average annual Total Current Liabilities growth rates for Uniqure NV have been 19% over the past three years , 20% over the past five years , and 18% over the past ten years .

Back to Top